Kuballa NMR Spectroscopy Transitions to Multi-Analysis Method
Summary
FDA filed a response to a petition from Kuballa regarding NMR spectroscopy methodology transitioning to a multi-analysis method. The document, filed under docket FDA-2026-P-4112, is available as a downloadable PDF attachment. No compliance obligations, deadlines, or penalties are stated in the available source content.
What changed
The source consists of a regulations.gov landing page with a PDF download link. The filing appears to be FDA's response to a petition concerning NMR spectroscopy methodology. No substantive regulatory text, compliance obligations, deadlines, or penalties are visible in the available content.
Affected parties should download the PDF attachment to review the full content of FDA's response to the Kuballa petition. No immediate action is required based solely on the visible source content.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mentioned entities
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.